Lonza Group AG
Research Lonza Group AG (LONN) on Bullrun: market cap CHF 39.56B, P/E 37.5, dividend yield 0.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLONN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyCHF
- Market capCHF 39.56B
- P/E37.5
- Dividend yield0.9%
- Financial periodFY2025
- RevenueCHF 6.53B
- Revenue growth19.2%
- Net income-CHF 275.00M
- Free cash flow-CHF 217.00M
- Gross margin35.4%
Valuation Snapshot
latest market cap is CHF 39.56B; P/E is 37.5; dividend yield is 0.9%.
Peer valuation comparison
Latest P/E is 37.53x versus a Healthcare sector median of 24.67x (52.2% above).
Latest dividend yield is 0.88% versus a Healthcare sector median of 1.84% (52.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 6.53B | -CHF 275.00M | -CHF 217.00M | 35.4% | n/a | CHF 719.00M | CHF 4.54B | CHF 7.91B |
| FY2024 | CHF 5.48B | CHF 636.00M | -CHF 143.00M | 32.7% | 8.92 | CHF 1.11B | CHF 5.12B | CHF 9.33B |
| FY2023 | CHF 6.72B | CHF 654.00M | -CHF 294.00M | 29.0% | 8.88 | CHF 1.47B | CHF 3.13B | CHF 9.45B |
| FY2022 | CHF 6.22B | CHF 1.22B | -CHF 852.00M | 39.2% | 16.34 | CHF 1.34B | CHF 2.59B | CHF 10.60B |
| FY2021 | n/a | n/a | n/a | n/a | 39.52 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-13 | CHF 39.56B | 37.5 | 0.9% | 5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 5 CHF, yield 0.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 4 CHF |
| FY2024 | 4 CHF |
| FY2023 | 3.5 CHF |
| FY2022 | 3 CHF |
| FY2021 | 3 CHF |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing;
ETFs that hold Lonza Group AG
Lonza Group AG is one of the ten largest holdings of 39 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares Core SPI ETF (CH) | 2.17% | 0.10% |
| UBS SMI ETF CHF dis | 2.75% | 0.20% |
| UBS Core SPI ETF CHF dis | 2.14% | 0.09% |
| Xtrackers Switzerland UCITS ETF 1D | 2.74% | 0.30% |
| UBS SPI ESG ETF CHF acc | 1.91% | 0.12% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.48% | 0.40% |
| iShares SMI ETF (CH) | 2.75% | 0.35% |
| Xtrackers Switzerland UCITS ETF 1C | 2.74% | 0.30% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lonza Group AG's market cap?
Lonza Group AG's market capitalization is CHF 39.56B.
What is Lonza Group AG's P/E ratio?
Lonza Group AG's price-to-earnings (P/E) ratio is 37.5.
Does Lonza Group AG pay a dividend?
Lonza Group AG has a dividend yield of 0.9%.
What does Lonza Group AG do?
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.